DCGI gives greenlight to Covaxin phase 2,3 trials for 2 to 18 year-olds
Category: #headlines  | By Mateen Dalal  | Date: 2021-05-17 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

DCGI gives greenlight to Covaxin phase 2,3 trials for 2 to 18 year-olds

The DCGI (Drugs Controller General of India) has reportedly approved Hyderabad-based firm Bharat Biotech's proposal to conduct Phase 2 and 3 clinical trials of the COVID-19 vaccine, Covaxin, among children aged 2 to 18 years.

In the trial involving 525 healthy volunteers, the vaccine will be administered intramuscularly in two doses on day 0 and day 28, sources cited.

The Subject Expert Committee (SEC) reviewed the proposal on February 24 at a meeting, asking the company to submit a revised clinical trial protocol. Bharat Biotech's Covaxin, in association with the Indian Council of Medical Research (ICMR), is currently in use in India’s COVID-19 vaccination drive for adults.

For the record, apart from Covaxin, the Covishield vaccine from the Serum Institute of India (SII) is being used to vaccinate people in India.

The vaccine, backed by Russia's sovereign wealth fund, the Russian Direct Investment Fund (RDIF), has also obtained regulatory approval in India to manufacture and sell its vaccine Sputnik V. Indian multinational pharmaceutical firm, Dr. Reddy, will oversee its vaccine operations in the country.

Bharat Biotech and SII have put forth their four-month production plan to the DGCI as various states continue to report COVID-19 vaccine shortages. While Serum Institute claims it can raise production to 10 crore doses, Bharat Biotech said they could ramp up production to 7.8 crore doses by August.

It is worth noting that the company’s Covaxin reported a 78% efficiency rate against the COVID-19 virus in an early review of phase 3 clinical trials in April. Moreover, the vaccine is seen to effective against some of the fast-spreading strains that are infecting millions of Indians.

The Hyderabad-based company stated that the vaccine is 100% efficient against critical coronavirus disease, implying that those who receive it would not experience severe symptoms or need hospitalization.

Source Credit –

https://www.businesstoday.in/coronavirus/dcgi-nod-to-phase-23-clinical-trials-of-covaxin-in-age-group-of-2-18-years/story/438948.html

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Celcom and Digi unite to drive digitalization for consumers, businesses

Celcom and Digi unite to drive digitalization for consumers, businesses

By Mateen Dalal

Axiata Group Bhd or Axiata and Digi.Com Bhd are anticipating the potential of their proposed merger company, which is expected to be known as Celcom Digi Bhd, for solidifying the capacity to accelerate digitization for businesses, consumers, and the ...

QRCS & WHO offer mental health support to Syrians affected by COVID-19

QRCS & WHO offer mental health support to Syrians affected by COVID-19

By Mateen Dalal

The representation office of the Qatar Red Crescent Society (QRCS) housed in Gaziantep, Turkiye will reportedly deploy three mobile mental health clinics in Syria. Backed by the funding from the World Health Organization (WHO), QRCS will ensure th...

Triple M pursues 1.5 GW of solar & wind energy projects in Egypt

Triple M pursues 1.5 GW of solar & wind energy projects in Egypt

By Mateen Dalal

Triple M is eyeing several projects in Egypt to help them produce electricity using renewable energy sources with a capacity of 1.5 GW inside and outside the country. It would be imperative to note that the projects being pursued by the company sh...